The count of EpCAM- carcinoembryonic antigen (CEA)+ cells was significantly higher in gastric cancer patients with stage II-III and IV compared to those with stage I. Patients with high EpCAM-CEA+ cell counts had a reduced 3-year RFS. This evidence concerns the gene CEACAM5 and gastric cancer.